Payment overview · 2025
General Payments
$493.84
24 reported records · 10 companies
Healthcare provider profile · identity verified
Nicholas Scott Yozamp, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1275914475
Verified facts
What the public records show
CMS Open Payments records show Nicholas Scott Yozamp, MD received $493.84 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 351 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 353 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 312 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $112.70 | 22.8% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $91.72 | 18.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $78.19 | 15.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.01 | 12.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.86 | 10.3% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $22.74 | 4.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.69 | 4.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.34 | 4.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $19.78 | 4.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.81 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $493.84 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $96.58 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $96.58 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $91.72 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.01 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.13 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $50.86 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $37.87 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 351 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 166 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 353 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 312 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
351 | 82 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
166 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
166 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
353 | 63 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
142 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
312 | 80 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1391 | 384 |
| Levothyroxine Sodium | Levothyroxine Sodium | 833 | 204 |
| Amlodipine Besylate | Amlodipine Besylate | 814 | 222 |
| Losartan Potassium | Losartan Potassium | 469 | 122 |
| Lisinopril | Lisinopril | 448 | 120 |
| Metformin Hcl | Metformin Hcl | 404 | 114 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 381 | 113 |
| Omeprazole | Omeprazole | 374 | 103 |
| Mounjaro | Tirzepatide | 353 | 63 |
| Farxiga | Dapagliflozin Propanediol | 351 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 335 | 92 |
| Alprazolam | Alprazolam | 331 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 319 | 91 |
| Ozempic | Semaglutide | 312 | 80 |
| Gabapentin | Gabapentin | 302 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 291 | 82 |
| Tamsulosin Hcl | Tamsulosin Hcl | 288 | 78 |
| Simvastatin | Simvastatin | 279 | 74 |
| Ezetimibe | Ezetimibe | 275 | 80 |
| Allopurinol | Allopurinol | 268 | 66 |
| Trazodone Hcl | Trazodone Hcl | 256 | 71 |
| Eliquis | Apixaban | 255 | 49 |
| Glipizide Er | Glipizide | 229 | 62 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 226 | 81 |
| Escitalopram Oxalate | Escitalopram Oxalate | 223 | 62 |
| Meloxicam | Meloxicam | 223 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 194 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 185 | 45 |
| Furosemide | Furosemide | 177 | 54 |
| Glimepiride | Glimepiride | 177 | 52 |
| Metformin Hcl Er | Metformin Hcl | 171 | 51 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 169 | 51 |
| Synthroid | Levothyroxine Sodium | 167 | 35 |
| Jardiance | Empagliflozin | 166 | 38 |
| Tramadol Hcl | Tramadol Hcl | 159 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 149 | 31 |
| Trulicity | Dulaglutide | 142 | 36 |
| Azithromycin | Azithromycin | 140 | 119 |
| Sertraline Hcl | Sertraline Hcl | 135 | 35 |
| Finasteride | Finasteride | 129 | 30 |
| Montelukast Sodium | Montelukast Sodium | 128 | 31 |
| Potassium Chloride | Potassium Chloride | 120 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 43 |
| Fenofibrate | Fenofibrate | 113 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 49 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 111 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 107 | 32 |
| Glipizide | Glipizide | 105 | 26 |
| Famotidine | Famotidine | 99 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 38 |
| Atenolol | Atenolol | 89 | 25 |
| Carvedilol | Carvedilol | 89 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 21 |
| Bupropion Xl | Bupropion Hcl | 87 | 23 |
| Spironolactone | Spironolactone | 85 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 25 |
| Januvia | Sitagliptin Phosphate | 79 | 17 |
| Lorazepam | Lorazepam | 79 | 24 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 75 | 16 |
| Celecoxib | Celecoxib | 74 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 74 | 30 |
| Terazosin Hcl | Terazosin Hcl | 72 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 60 |
| Humalog | Insulin Lispro | 71 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 14 |
| Alendronate Sodium | Alendronate Sodium | 65 | 23 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 65 | 65 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 63 | 21 |
| Irbesartan | Irbesartan | 63 | 18 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 63 | 17 |
| Warfarin Sodium | Warfarin Sodium | 63 | 11 |
| Novolog | Insulin Aspart | 60 | 14 |
| Clonazepam | Clonazepam | 57 | 12 |
| Prednisone | Prednisone | 57 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 55 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 15 |
| Enalapril Maleate | Enalapril Maleate | 53 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 53 | 16 |
| Valsartan | Valsartan | 52 | 14 |
| Azelastine Hcl | Azelastine Hcl | 51 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 49 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 21 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 45 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | 15 |
| Propranolol Hcl | Propranolol Hcl | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 14 |
| Diazepam | Diazepam | 42 | suppressed |
| Lovastatin | Lovastatin | 42 | 12 |
| Novolog Flexpen | Insulin Aspart | 41 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 14 |
| Valacyclovir | Valacyclovir Hcl | 40 | 22 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 11 |
| Buspirone Hcl | Buspirone Hcl | 38 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 17 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 35 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 23 |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 17 |
| Bydureon Bcise | Exenatide Microspheres | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 29 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Testosterone | Testosterone | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | 11 |
| Lagevrio (Eua) | Molnupiravir | 22 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Indapamide | Indapamide | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 15 |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Ciclopirox | Ciclopirox | 16 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Dupixent Pen | Dupilumab | 14 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Crestor | Rosuvastatin Calcium | 13 | suppressed |
| Edarbi | Azilsartan Medoxomil | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $493.84 · 24 records | Novo Nordisk Inc | Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, Ozempic, REPATHA, Rybelsus, Tymlos, UNITHROID, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error